Antacids Market (2026 - 2033)

Antacids Market Summary

The global antacids market size was valued at USD 8.1 billion in 2025 and is projected to grow from USD 8.4 billion in 2026 to USD 11.4 billion in 2033, at a CAGR of 4.4% from 2026 to 2033. North America is the largest market for antacids, with a revenue share of 45.0% in 2025. Changing dietary habits is among the major factors expected to fuel the growth of the market during the forecast period.

The increasing prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and various other digestive disorders, which result in acidity, digestion problems, and heartburn are also expected to drive the market. According to a study published by the National Institutes of Health (NIH) in 2022, 783.95 million people were diagnosed with GERD globally in 2019. The total number of years of life lived with disability (YLD) increased by 77.19%, whereas the total number of prevalent cases increased by 77.53%, and the total number of incident cases increased by 74.79% from 1990 to 2019.

Furthermore, increasing awareness about GERD is anticipated to boost the market growth. According to an article published in the International Foundation for Gastrointestinal, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) encourages patients suffering from GERD-related symptoms, to consult their physicians.

Other factors include rising awareness and availability of over-the-counter (OTC) antacids that offer quick and effective relief from these symptoms and the growing geriatric population that is more prone to digestive issues and requires frequent use of antacids. Changing dietary habits and lifestyle factors such as stress, smoking, alcohol consumption, and obesity that contribute to the development of acid-related disorders can also affect the growth of the market.

In the geriatric population, acid complications create a unique challenge for both general practitioners and gastroenterologists. Moreover, such patients often suffer from various symptomatic disorders such as Barrett's esophagus, and esophageal cancer. For the treatment of such disorders, a combination of treatments is used and the use of antacids in such cases has increased significantly, which is expected to drive the market growth over the forecast period.

Market Dynamics

Opportunities

Antacids were previously available only in tablets, liquids, and powders; however, researchers have now developed a mouth-melting antacid consisting of micro granules that dissolve easily in the mouth. These granules integrate the effects of the herbal ingredients contained with the latest melting technology. Mouth-melting antacids are a new trend in the market for antacids, which is expected to provide a lucrative opportunity for market growth during the forecast period. For instance, Pepmelt, an instant mouth-melting powder manufactured by Sun Pharmaceuticals Ltd., gives quick relief to the consumer.

Analyst Perspective

Increasing demand for products that can offer immediate relief from acid reflux and associated health problems is anticipated to provide strong growth potential for this market. In addition, growing inclusion of medicines in ongoing treatments of chronic diseases that might lead to acid reflux when consumed frequently for longer time may also contribute to increased demand for antacids in coming years. Easy accessibility facilitated by growing footprint of retail pharmacies is expected to support further growth of this market during forecast period. Key market participants may embrace novel technologies and innovation-based administration methods to improve engagements.

Type Insights

The tablets segment dominated the market with the largest revenue share in 2025. The presence of chewable tablets in different flavors helps in improving patient adherence to the medication. In addition, tablets can provide the exact amount of dosage to the patients compared to other dosage forms and also they are easy to store compared to other counterparts. These factors can be attributed to the segment growth over the forecast period. Some well-known brands of chewable tablets include TUMS, manufactured by the Haleon Group of Companies; Alka-Seltzer, manufactured by Bayer AG; and Rolaids, manufactured by Sanofi Consumer Healthcare.

Strict regulations regarding formulations, labeling, and other elements associated with medicines have been stimulating reformulations, product relaunches, and enhanced R&D efforts in this market. For instance, in November 2025, the U.S. Food and Drug Administration announced approval for reformulated ranitidine tablets, which marked return of widely used acid-reducing medicine the U.S. industry. Such developments highlight the growth trends in this market.

The liquid segment is expected to grow at a significant CAGR over the forecast period. The presence of key players, such as Pfizer Inc., GlaxoSmithKline plc. and Dabur offering liquid antacids is estimated to boost the segment growth. Also, the liquid dosage form is one of the most favored choices for children and the elderly population due to its palatable taste. This factor is also anticipated to foster market growth.

End Use Insights

By end use, the retail pharmacy segment held the largest revenue share in 2025. Easy accessibility, increasing number of retail pharmacies operated by organized retail businesses, and assistance provided by local pharmacist in making right choices for OTC medicines, are some of the key growth drivers for this segment. Retail pharmacies have been offering variety of products with similar symptom relief properties, which enables additional choices for the patients, leading to greater engagements.

Presence of large retail businesses in this segment is anticipated to fuel growth in forecast period. Multiple large-scale operators in retail industry have been adopting automation and enhanced warehousing techniques to develop competitive advantage over others. For instance, in May 2025, Walmart announced opening of its centralized prescription processing facility, spanning across 102,000-square-foot, in Frederick, Maryland. The facility is developed to address 100,000 prescriptions each day, to facilitate seamless operational support for nearly 700 stores across multiple states. It also announced ongoing facility developments in Phoenix, Arizona and Republic, Missouri. Such advancements are likely to support growth of retail pharmacy segments in this market.

Online pharmacy is anticipated to grow at the fastest CAGR over the forecast period, owing to perks such as quick home delivery, diversity in options for goods, better pricing, and discounts. Some of the top online pharmacy companies in the U.S. include Sesame, Amazon Pharmacy, CVS, Pill Pack, Blink Health, and GeniusRx. In February 2026, Amazon announced its plans to expand same-day prescription delivery through Amazon Pharmacy to 4,500 U.S. locations by the end of 2026. Such developments are expected to support segment growth during the forecast period.

Regional Insights

North America Antacids Market Trends

North America antacids industry holds the largest revenue share of the antacids market in 2025. This is attributed to a well-established healthcare system and infrastructure, easy information availability, and a strong retail pharmacy presence in the region. In addition, the presence of multiple companies engaged in the manufacturing and marketing of antacids in the regions also contributes to the growth experienced by this regional industry.

Asia Pacific Antacids Market Trends

Asia Pacific antacids industry is projected to register the fastest CAGR over the forecast period, which is attributed to high unmet clinical needs, increasing awareness about the immediate relief benefits offered by the antacids, and the growing network of retail pharmacies in countries such as India and China. The presence of various manufacturing organizations such as Haleon, Reckitt Benckiser, Sanofi, Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and others also adds significant strength to the region’s growth potential.

Key Antacids Company Insights

The competitive environment of the market is highly fragmented, with the presence of several multinational players and small-scale companies, competing to gain higher market share. New product launches, geographical expansion, and joint ventures are some of the key strategies undertaken by key players in the market.

Key Antacids Companies

The following key companies have been profiled for this study on the antacids market.

• GSK plc.

• Bayer AG

• Boehringer Ingelheim International GmbH

• Dr. Reddy’s Laboratories Ltd.

• Sanofi

• Reckitt

• Sun Pharmaceutical Industries Ltd.

• Takeda Pharmaceutical Company Limited

• Pfizer Inc.

• Procter & Gamble

Recent Developments

• In January 2026, Wonderbelly, one of the digestive health company, engaged in clean-label product developments, was acquired by Procter & Gamble. Becoming part of P&G’s personal health care portfolio, Wonderbelly is expected to strengthen P&G position in consumer health industry.

• In July 2024, Phathom Pharmaceuticals, a biopharmaceutical company dedicated to the development and market launch of next-generation therapies for gastric acid disorders, announced the approval of the FDA for VOQUEZNA (vonoprazan) 10 mg tablets, which are used to reduce the heartburn related to Gastroesophageal Reflux Disease (GERD) in adults.

Antacids Market Report Scope

Global Antacids Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antacids market report based on type, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Tablet

  • Liquid

  • Others

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait